Selumetinib in Combination With Gefitinib in NSCLC Patients

NCT02025114 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: selumetinib

Sponsor

National Taiwan University Hospital